Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to sharpen diagnosis of celiac disease using AI and genetics

NCT ID NCT07556328

Knowledge-focused Sponsor: Tampere University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting small intestine tissue samples from 300 adults to better understand and diagnose celiac disease and other small-bowel conditions. Researchers will use advanced techniques like AI image analysis and genetic profiling to create more reliable diagnostic tools. Participants include healthy individuals, those being tested for celiac disease, and patients with persistent gut damage despite a gluten-free diet.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more accurate and faster diagnosis of celiac disease and better ways to monitor treatment response.
What could go wrong
This is an observational study, not testing a new treatment. The findings may not directly change patient care for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy, seropositive patients and refractory to treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Clinically indicated upper gastrointestinal endoscopy (gastroscopy) * Written informed consent obtained prior to procedure * For Group 1 (Healthy Controls): Negative celiac disease antibodies (anti-transglutaminase and/or anti-endomysium); no suspected celiac * For Group 2 (Celiac Diagnostics): Referred for primary celiac disease diagnostics requiring duodenal biopsy * For Group 3 (Refractory Injury): Confirmed small-bowel mucosal injury not responsive to a gluten-free diet Exclusion Criteria: * For Group 1 (Healthy Controls): Other small-bowel diseases causing mucosal injury, including Crohn's disease and small-bowel ulcers * Inability to provide written informed consent * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Celiac disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

celiac disease refractory celiac disease small intestine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Celiac disease Refractory celiac disease Small bowel disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hatanpää Specialist Medical Care

    RECRUITING

    Tampere, 33720, Finland

  • Tampere University Hospital (Tays)

    RECRUITING

    Tampere, 33720, Finland

  • Valkeakoski Regional Hospital

    RECRUITING

    Valkeakoski, 33720, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.